• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket

    6/21/24 8:22:44 AM ET
    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $BRNS alert in real time by email

    Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above.

    Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy.
    • DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed for Chapter 11 protection and implemented a 20% workforce reduction to preserve cash.
    • Trinity Place Holdings Inc. (NYSE:TPHS) shares rose 35.7% to $0.1740 in pre-market trading after gaining more than 5% on Thursday.
    • Barinthus Biotherapeutics PLC – ADR (NASDAQ:BRNS) shares rose 25.5% to $1.57 in pre-market trading after dipping 26% on Thursday.
    • Zoomcar Holdings, Inc. (NASDAQ:ZCAR) rose 22.5% to $0.1791 in pre-market trading. Zoomcar announced closing of sale of $3.6 million notes private placement.
    • Ondas Holdings Inc. (NASDAQ:ONDS) gained 16.6% to $0.77 in pre-market trading after declining around 10% on Thursday.
    • Lion Group Holding Ltd – ADR (NASDAQ:LGHL) shares gained 13.1% to $0.44 in pre-market trading.
    • Solid Biosciences Inc (NASDAQ:SLDB) shares rose 11.9% to $7.05 in pre-market trading after falling over 7% on Thursday.
    • Clover Health Investments, Corp. (NASDAQ:CLOV) shares climbed 7.8% to $1.11 in pre-market trading following insider buying from the company's co-founder. After the market close on Thursday, Clover Health filed a Form 4 with the SEC showing that co-founder and executive chair Vivek Garipalli purchased 877,567 shares of Clover Health stock at an average price of $1.14 per share.

    Losers

    • Psyence Biomedical Ltd. (NASDAQ:PBM) shares fell 23.6% to $0.4547 in pre-market trading after gaining 6% on Thursday.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) shares fell 21.1% to $0.5102 in pre-market trading after dipping around 14% on Thursday.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares declined 18.5% to $0.1310 in pre-market trading after gaining 35% on Thursday.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) shares fell 17.6% to $0.4544 in pre-market trading.
    • Reliance Global Group, Inc. (NASDAQ:RELI) shares fell 16.8% to $0.5021 in pre-market trading. Reliance Global shares jumped 54% on Thursday after the company announced an institutional investor has redeemed all of its outstanding Series B and Series G warrants.
    • MGO Global, Inc. (NASDAQ:MGOL) fell 16% to $0.6296 in pre-market trading. MGO Global shares jumped 63% on Thursday after the company and Heidmar entered an agreement for a business combination.
    • Trevena, Inc. (NASDAQ:TRVN) shares declined 13.1% to $0.2138 in pre-market trading after dipping over 30% on Thursday. Trevena announced preclinical TRV045 data for long-term analgestic effect in prelinical model of neuropathic pain.
    • Molecular Partners AG (NASDAQ:MOLN) shares dipped 12.7% to $9.61 in pre-market trading after jumping over 38% on Thursday.
    • NANO Nuclear Energy Inc. (NASDAQ:NNE) shares fell 9.7% to $13.74 in pre-market trading after surging 31% on Thursday.
    • VinFast Auto Ltd. (NASDAQ:VFS) fell 7.9% to $3.97 in pre-market trading after gaining 10% on Thursday.

    Now Read This: Top 4 Consumer Stocks that May Keep You Up At Night This Month

    Get the next $BRNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRNS
    $CLOV
    $DMTK
    $ENSC

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Molecular Partners AG
    $MOLN
    1/27/2026$13.00Buy
    H.C. Wainwright
    Ondas Inc.
    $ONDS
    12/16/2025$13.00Buy
    Stifel
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    Ondas Inc.
    $ONDS
    11/14/2025Perform → Outperform
    Oppenheimer
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Ondas Inc.
    $ONDS
    10/6/2025$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Reynoso Jamie L.

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    3/18/26 6:11:18 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Tham Chee Soon

    3 - VinFast Auto Ltd. (0001913510) (Issuer)

    3/18/26 4:30:29 PM ET
    $VFS
    Auto Manufacturing
    Industrials

    SEC Form 3 filed by new insider Vuong Pham Nhat

    3 - VinFast Auto Ltd. (0001913510) (Issuer)

    3/18/26 4:30:17 PM ET
    $VFS
    Auto Manufacturing
    Industrials

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    SEC Filings

    View All

    SEC Form S-3 filed by Solid Biosciences Inc.

    S-3 - Solid Biosciences Inc. (0001707502) (Filer)

    3/19/26 5:04:40 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Solid Biosciences Inc.

    S-3 - Solid Biosciences Inc. (0001707502) (Filer)

    3/19/26 5:03:02 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Solid Biosciences Inc.

    S-8 - Solid Biosciences Inc. (0001707502) (Filer)

    3/19/26 4:10:52 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Molecular Partners AG with a new price target

    H.C. Wainwright initiated coverage of Molecular Partners AG with a rating of Buy and set a new price target of $13.00

    1/27/26 8:47:34 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel initiated coverage on Ondas Holdings with a new price target

    Stifel initiated coverage of Ondas Holdings with a rating of Buy and set a new price target of $13.00

    12/16/25 9:00:51 AM ET
    $ONDS
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $998,997 worth of shares (446,980 units at $2.23), increasing direct ownership by 32% to 1,856,247 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/8/25 4:07:07 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    3/13/25 4:05:03 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    - Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 - - Company anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026; additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003 - - Friedreich's Ataxia (SGT-212): First participant dosed in the Phase 1b FALCON trial; SGT-212 has been well tolerated with no treatment-related adverse events - - CPVT (SGT-501): Clinical s

    3/19/26 4:12:05 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

    – Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approval Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions with the U.S. Food and Drug Administration (FDA) regarding AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). Sarepta requested a meeting with FDA to discuss submitting supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of AMONDYS 45 and VYONDYS 53 to tradition

    3/19/26 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients

    SAN FRANCISCO, March 19, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company"), and a leading AI-powered physician-enablement platform today released a whitepaper titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Flu Preventative Care." The analysis examines the role of CA's real-time clinical insights on immunization rates and flu-related acute care utilization within Clover Health's Medicare Advantage (MA) population. Influenza remains a major cause of morbidity among Medicare beneficiaries, with 90% to 95% of flu-re

    3/19/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Financials

    Live finance-specific insights

    View All

    VinFast Reports Preliminary and Unaudited Fourth Quarter and Full Year 2025 Financial Results

    SINGAPORE, March 16, 2026 /PRNewswire/ -- VinFast Auto Ltd. ("VinFast" or the "Company") (NASDAQ:VFS), a pure-play electric vehicle ("EV") manufacturer with the mission of making EVs accessible to everyone, today announced its preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2025.  EV deliveries were 86,557 in the fourth quarter of 2025, representing a 127% increase quarter-over-quarter and a 63% increase year-over-year. Among those, the commercial models under the Green brand and the EC Van model accounted for approximately 49%

    3/16/26 10:43:00 AM ET
    $VFS
    Auto Manufacturing
    Industrials

    Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

    Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company's base of high caliber institutional investors, expected to complete in the second quarter of 2026Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026 GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today announced its financial results for the year ended December 31, 2025, and provided an overview of the Company's co

    3/13/26 8:00:00 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Defense Sector Turns to Drone-as-a-Service as Military Forces Seek Faster, Smarter Intelligence Solutions

    Growing reliance on real-time intelligence, surveillance, and reconnaissance is accelerating demand for scalable drone service platforms across defense operations worldwideNEW YORK, March 12, 2026 /CNW/ -- Market News Updates News Commentary -  Drones are becoming a much bigger part of modern defense operations, and a growing trend within this space is Drone-as-a-Service (DaaS). Instead of militaries buying, maintaining, and operating every drone themselves, they can now work with specialized providers that supply the drones, pilots, software, and data analytics as a service. This approach allows defense organizations to quickly deploy drone capabilities for missions such as surveillance, re

    3/12/26 9:00:00 AM ET
    $EH
    $ONDS
    $UAVS
    Aerospace
    Industrials
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Leadership Updates

    Live Leadership Updates

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANO Nuclear Expands its Nuclear Policy Leadership Expertise with the Appointment of U.S. Government Veteran Sarah Lennon as its International Nuclear Policy Advisor

    New York, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ:NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor (MMR) and technology company focused on developing clean energy solutions, today announced the appointment of Sarah Lennon as its International Nuclear Policy Advisor. Sarah is a seasoned national security and nuclear energy policy leader with three decades of distinguished service across the U.S. Government, bringing deep expertise in nuclear security, nonproliferation, international cooperation, and strategic planning. "It is a pleasure to join the NANO Nuclear team," said Sarah Lennon, International Nuclear Policy A

    2/20/26 8:30:00 AM ET
    $NNE
    Electric Utilities: Central
    Utilities

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRNS
    $CLOV
    $DMTK
    $ENSC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care